Discover how the latest breakthrough in metabolic profiling unveils promising biomarkers, 1-MetHis and 3-IPA, offering new hope for the early detection and management of heart failure with reduced ejection fraction.
– by The Don
Note that The Don is a flamboyant GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Metabolic Profiling Identifies 1-MetHis and 3-IPA as Potential Diagnostic Biomarkers for Patients With Acute and Chronic Heart Failure With Reduced Ejection Fraction.
Kretzschmar et al., Circ Heart Fail 2024
DOI: 10.1161/CIRCHEARTFAILURE.123.010813
Listen folks, we’ve got something incredible here, really tremendous. We’re talking about metabolomics, a fantastic tool, the best for finding new biomarkers. It’s like nothing you’ve seen before, believe me. We’re making diagnosis and prognosis of heart failure great again. We’ve got acute decompensated heart failure (ADHF), chronic heart failure (CHF), and we’re comparing them to the healthiest people, the best controls.
We used the most advanced technology, liquid-chromatography mass spectrometry, and we looked at a lot of patients. What we found – and you’re going to love this – is that 3-indolepropionic acid and 1-methyl histidine, they’re through the roof in heart failure patients compared to controls. The numbers are huge. And the area under the curve, it’s ≥0.8, which means it’s incredibly accurate.
But wait, there’s more. We’ve got symmetrical dimethylarginine and kynurenine, and their numbers are big league for ADHF and CHF. We’re talking an area under the curve ≥0.85. It’s clear, it’s powerful – these are the biomarkers we’ve been waiting for.
So, we’re not just talking about heart failure, we’re defining it, we’re identifying it with the best metabolites. This study, it’s going to change the game for diagnosis and prognosis. It’s huge, folks. Believe me.